Stem Cell Transplant and Cellular Therapies Symposium 2026: Navigating a Rapidly Changing Landscape
- Continuing Education
Enhance your ability to manage capacity effectively by gaining essential knowledge and strategies to streamline care and improve outcomes for patients undergoing stem cell transplants or CAR T-cell therapies.
- Live Online or In Person
This course is taught in person and online in real time.
Dana-Farber’s Yawkey Center for Cancer Care, Conference Center, 3rd Floor, Rooms 306/307 | 450 Brookline Avenue, Boston, MA
$75
This is the standard price, for a full list of profession pricing see below.
View All
Continuing Education
Earn up to:
7.50 AMA PRA Category 1 Credit(s) ™
View All
One Day
Please view the Schedule for a full description of the program.
On This Page
Overview
This symposium will provide participants with an overview of the current state and future direction of transplant, cellular, and gene therapies. Through expert presentations and interdisciplinary discussion, attendees will gain insights into emerging clinical advances, evolving care delivery models, and opportunities to enhance patient access and outcomes. The program is designed to support health care professionals in navigating a rapidly changing therapeutic landscape while fostering collaboration across the continuum of care.
Learning Objectives
- Expand community access through shared-care education, referral partnerships, and site-of-care alignment.
- Prepare for evolving cell/gene therapy and myeloma care, including ID management and emerging pipeline innovations.
- Explore NMDP/HLA Today donor and allo-referral processes, including APP utilization and family donor criteria.
- Optimize lymphoma referral pathways and current-state treatment coordination.
- Implement telemedicine best practices and adapt to evolving Medicare rules.
Developed and Offered By:
Continuing Education courses are developed by faculty from Harvard Medical School's teaching hospitals and accredited by Harvard Medical School. This course is offered by Dana-Farber Cancer Institute.
Who Should Participate
Nurses, Nurse Practitioners, Specialty Physicians, Hematology Oncologists, Physician Assistants, Primary Care Physicians, and Social Workers
Schedule
All agenda sessions are in Eastern Time.
Friday, October 16, 2026
Breakfast
8:00-8:20 am
Welcome, Introduction to Today's Session
8:20-8:30 am
Opportunities for Expanding Access into the Community: Achieving Operational Excellence
8:30-9:30 am
Optimizing Lymphoma Treatment and Referrals: Where We Are Today
9:30-10:15 am
NMDP Pathways to Transplant, HLA Today and Donor Services
10:15-11:15 am
Lunch
11:15-11:30 am
Concepts and Resources to Support Remote Patient Management – Panel Discussion
11:30 am-12:15 pm
Infectious Disease Management in Transplant and Cell Therapies
12:15-1:15 pm
Gene Therapy: Lessons Learned
1:15-2:15 pm
Break
2:15-2:30 pm
Changing Landscape: Multiple Myeloma
2:30-3:30 pm
What’s Coming Down the Pipeline
3:30-4:20 pm
Closing Remarks
4:20-4:30 pm
Faculty
Harvard Medical School Continuing Education offers faculty who are international experts and leading educators in their fields. As a student in this course, you’ll have access to outstanding course directors and faculty.
Course Directors
Corey Cutler, MD, MPH
Course Director
- Director, Adult Stem Cell Transplantation Program
Amy Browning Emmert, MScPH
Course Director
- Executive Director, Cell Therapies External Affairs
Kaitlen Reyes, DNP, APRN, FNP-C, AOCNP
Course Director
- Dana-Farber Cancer Institute
Greg Bourdeau
Technical Principal, Cell Therapy Donor Services
Jose Cancelas, MD, PhD
Director of Connell and O'Reilly Families Cell Manipulation Core Facility
Amy Emmert, MScPH
Executive Director for Cellular Therapy External Affairs
Amy Joyce, MSN, AOCN, NP
Cellular Therapies
Amar Kelkar, MD, MPH
Physician, Adult Stem Cell Transplantation Program
Leslie Lehmann, MPH
Clinical Director, Pediatric Stem Cell Transplantation Program
Jessica Little, MD
Transplant/Oncology Infectious Diseases Physician
Medical Director of Antimicrobial Stewardship, Brigham and Women’s Hospital
Associate Director Non-Oncology Cell and Gene Therapy, Mass General Brigham Office of Clinical Research
John Manis, MD
Associate Director, Transfusion Medicine, Boston Children’s Hospital
Kidest Mequanent, MHA
Network Manager, Cell Therapies
Clifton Mo, MD
Director of Autologous Stem Cell Transplantation for Multiple Myeloma
Omar Nadeem, MD
Clinical Director, Myeloma Immune Effector Cell Therapy Program
Clinical Director, Center for Early Detection and Interception of Blood Cancers
Sarah Nikiforow, MD, PhD
Technical Director, Immune Effector Cell Therapy Program
Medical Director, Connell and O’Reilly Families Cell Manipulation Core Facility
Michelle Noiles, PA-C
Hematological Malignancies & Cellular Therapies
Julie Porter, MS
Vice President, Cellular Therapies Operations
David Qualls, MD
Physician, Division of Lymphoma
Linda Ramsdell, MSN, FNP-BC, OCN
Assistant Program Director of Immune Effector Cellular Therapy
John Reagan, MD
Hematology Oncologist
Ankita Shah, NP
Medical Science Liaison, Patient and Provider Services, NMDP
Eric Smith, MD, PhD
Director of Translational Research, Immune Effector Cell Therapies
Request Information
Interested in learning more about this program? Sign up for details.
Course Fees
Registration Details
Dana-Farber Cancer Institute and Mass General Brigham staff are eligible for a registration discount. Contact kidest_mequanent@dfci.harvard.edu.
| Role | Course Fee |
|---|---|
| Physician (MD/DO) | $75 |
| Nurse (RN/APRN) | $75 |
| PA | $75 |
| Psychologist | $75 |
| Resident/Fellow | $75 |
| Social Worker | $75 |
| Allied Health Professional / Other | $75 |
Dana-Farber Cancer Institute and Mass General Brigham staff are eligible for a registration discount. Contact kidest_mequanent@dfci.harvard.edu.
Accreditation
The Harvard Medical School designates this Hybrid for a maximum of 7.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Harvard Medical School designates this Harvard Medical School designates this live activity for a maximum of 6.00 ANCC contact hours.
The National Commission on Certification of Physician Assistants (NCCPA) states that 6.00 AMA PRA Category 1 Credits™ are acceptable for continuing medical education requirements for recertification. We would also suggest that learners check with their state licensing board to ensure they accept reciprocity with AMA PRA Category 1 Credit™ for re-licensure.
The American Medical Association (AMA) has an agreement of mutual recognition of continuing medical education (CME) credit with the European Union of Medical Specialists (UEMS). Additional information regarding this agreement may be found on the Union of European Medical Specialists website.
The Royal College of Physicians and Surgeons of Canada recognizes conferences and workshops held outside of Canada that are developed by a university, academy, hospital, specialty society or college as accredited group learning activities.